title: Selective omission of the donor cross-match before renal transplantation: efficacy, safety and effects on cold storage time.
abstract: BACKGROUND
  A donor lymphocyte cross-match (XM) test performed before renal transplantation is considered mandatory but may delay the transplant and increase the cold storage time. With careful documentation of sensitizing events and with knowledge of previous antibody screening results, it is often possible to predict the XM result for a given donor HLA mismatch. In this study, a policy was adopted of omitting the pretransplant XM in patients in whom a negative result was predicted with absolute confidence.
  
  
  METHODS
  Recipients were selected for cadaveric donor kidney transplantation using a computer algorithm based on HLA match, sensitization status, time on the waiting list and donor and recipient age. The immediate pretransplant cross-match test was omitted in non-sensitized recipients and in sensitized recipients where antibody specificities were precisely defined and not against donor HLA.
  
  
  RESULTS
  From October 1997 to May 1999, 53 of 96 (55%) consecutive cadaveric kidney donor transplants were performed without a pretransplant XM. In all cases, a negative donor HLA-specific antibody XM was confirmed after transplantation. Omission of the pre-transplant XM was associated with a significant reduction in cold ischemic time (15.0 hr vs. 18.2 hr, P=0.01) and a reduced incidence of delayed graft function (13% vs. 33%, P=0.03). However, there was no difference in transplant outcome at 1 year.
  
  
  CONCLUSIONS
  Rigorous attention to priming events together with careful antibody screening allows the pre-transplant XM test to be safely omitted in approximately half the patients awaiting renal transplantation. This policy allows a modest reduction in cold ischemia time, but it remains to be seen whether this is of clinical benefit.
authors.affiliation: Department of Surgery, Addenbrooke's NHS Trust, Cambridge, United Kingdom.
authors.forename: C J
authors.initials: CJ
authors.lastname: Taylor
authors.forename: S I
authors.initials: SI
authors.lastname: Smith
authors.forename: C H
authors.initials: CH
authors.lastname: Morgan
authors.forename: S
authors.initials: S
authors.lastname: Stephenson
authors.forename: T
authors.initials: T
authors.lastname: Key
authors.forename: P
authors.initials: P
authors.lastname: Jones
authors.forename: C
authors.initials: C
authors.lastname: Watson
authors.forename: B
authors.initials: B
authors.lastname: Jacques
authors.forename: K I
authors.initials: KI
authors.lastname: Welsh
authors.forename: J A
authors.initials: JA
authors.lastname: Bradley
mesh_terms: D000328:Adult; D015925:Cryopreservation; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D007114:Immunization; D007515:Islets of Langerhans / Q000503:physiopathology; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D011300:Preoperative Care; D012449:Safety; D013997:Time Factors; D014019:Tissue Donors; D016896:Treatment Outcome